BRIDGEWATER, N.J., March 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and ...
JP Morgan upgraded Amneal to Overweight, raising its price target to $12, citing strong generics growth and expanding biosimilar adoption. How to Spot the Market Bottom: Matt Maley has navigated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback